Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts
Updated: December 7, 2025 Merck & Co., Inc. (NYSE: MRK) — the U.S. pharmaceutical company behind blockbuster cancer drug Keytruda and HPV vaccine Gardasil — has just wrapped up a busy early-December news cycle. The company closed a multi‑billion‑dollar debt